投资者关系活动 类别 ☑特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 ☑现场参观 □其他 （线上会议调研） 参与单位名称及 人员姓名 长城证券陈逸同、金鹰基金曾嘉诚 时间 2025 年 08 月 05 日 地点 公司会议室 上市公司接待人 员姓名 副总经理、董事会秘书邱蓉 证券办 李琼婷 投资者关系活动 主要内容介绍 一、公司情况介绍 二、公司情况交流 1、公司今年产能方面会考虑扩产吗？ 答：公司目前的产能利用率维持在较高水平，公司产品的产量 情况由整车销售情况决定，公司会根据定点项目的市场销量情 况增加产线、扩大产能以满足客户需求。 2、公司的线控制动产品何时放量？ 答：公司的线控制动产品目前已新增了项目定点，如于 2025 年 02 月 06 日、2025 年 06 月 04 日分别披露的《关于收到新 能源汽车定点通知的公告》，上述两个项目预计生命周期销售 总金额为 12 亿元，公司会根据客户的量产时间积极推进。 3、公司 EMB 产品目前的情况？ 1 | | 答：公司有 EMB 产品的技术储备，目前尚未量产，具体的市场 | | | | --- | --- | --- | ...

证券代码：002891 证券简称：中宠股份 | | □特定对象调研 □分析师会议 | | | --- | --- | --- | | 投资者关系活动 | □媒体采访 业绩说明会  | | | 类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他（请文字说明其他活动内容） | | | | 安本私算基金管理(上海)有限公司 | 严艾婧 | | | 北京才誉资产管理企业（有限合伙） | 韦一飞 | | | 北京诚旸投资有限公司 黄娴 | | | | 北京方圆金鼎投资管理有限公司 应文添 | | | | 北京汉和汉华资本管理有限公司 张婷婷 | | | | 北京金百镕投资管理有限公司 刘晓爽 | | | | 北京京管泰富基金管理有限责任公司 | 王欣伟 | | | 北京乐正资本管理有限公司 王慧怡 | | | 活动参与人员 | 北京神农投资管理股份有限公司 赵晚嘉 | 张智皓 | | | 北京橡果资产管理有限公司 魏鑫 | | | | 北京信伟达资产管理有限公司 张钧宇 | | | | 博道基金管理有限公司 陈磊 | | | | 渤海证券股份有限公司 袁艺博 | | | | 财通证 ...

Group 1: Company Branding and Market Positioning - The brand "Tianyoude" now accounts for over 50% of the company's proprietary Qingke liquor, leading to the name change to "Tianyoude Liquor" for consistency across branding and securities [3] - The company remains the largest producer of Qingke liquor, focusing on regional perceptions of Qingke and Qingke liquor for promotional strategies [3] Group 2: Market Expansion Strategies - The company is increasing its presence in markets outside Qinghai and Tibet, particularly in Gansu and Sichuan, by enhancing sales channels for products priced below 100 yuan [4] - New product development targets younger consumers, with recent launches including a 28-degree lemon Qingke liquor and a snow pear liquor to cater to diverse taste preferences [4] Group 3: Cost Management and Raw Material Sourcing - Fluctuations in raw material prices have been ongoing, but they do not significantly impact overall costs due to the low percentage of raw materials in total costs [5] - The company has established long-term agreements with farms to secure raw material supply and maintain market balance [5] Group 4: Product Sales Performance - Products priced above 100 yuan constitute approximately 50% of total sales, with a specific focus on the 500 yuan segment that has gained market recognition [6] - The company plans to invest 160 million yuan in expanding its winery in Tibet, leveraging tourism and unique cultural resources to enhance brand visibility [7][8] Group 5: Sales Channels and Profitability - The primary sales channels include direct sales and distribution, with online sales accounting for over 4% in 2024 [9] - In 2024, the company reported a revenue of 1,254.84 million yuan, a 3.69% increase, but a net profit decline of 52.96% to 42.14 million yuan due to increased market expenses and stock incentive plan impacts [10] - To improve profitability in 2025, the company is focusing on revenue growth and precise expense management, particularly in expanding lower-priced product channels [10] Group 6: Future Product Development - The company intends to maintain its focus on Qingke and explore new product lines such as fruit-flavored products and potentially Qingke champagne, responding to emerging consumer trends [11]

三博脑科医院管理集团股份有限公司 投资者关系活动记录表 编号：2025-003 | | ☑特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | ☑现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | 中信证券：沈睦均、张斌斌 | | | 东北证券：叶菁汇添富基金：毕宇倩 | | | 宝盈基金：杨明隽华宝基金：魏扬帆 | | | 长盛基金：黄施齐朱雀基金：徐睿潇 | | 人员姓名 | 华泰资管：朱新彦时真基金：张若昳 | | | 华创证券：孙芊荟招商证券：张语馨 | | | 国海证券：李明云能资本：张子帅 | | 时间 | 2025年8月5日14:00-16:00 | | 地点 | 云南省昆明市官渡区季宏路1790号昆明三博脑科医院2层会议室 | | | 副总经理、董事会秘书：胡卫卫 | | | 独立董事：蔡江南、张雅萍、杨争媛 | | 上市公司接待人 | 昆明三博副院长：卜风雷 | | 员姓名 | 昆明三博副院长、心脏中心主任、心外科主任：王忠明 | | | 证券事务 ...

Group 1: Blockchain Technology Applications - The company has developed a series of products and solutions based on blockchain technology, including supply chain finance, electronic documents, and clean energy traceability, successfully implemented in multiple power enterprises [2][3] - Projects like "Dian Yi Chain" and "Cai Zhi Chain" have received national management science awards, while "Li Min Chain" won the second prize in the Digital China Innovation Competition's blockchain track [2][3] - The company plans to continue investing in blockchain, focusing on technological innovation and ecosystem collaboration to enhance its products and solutions [3] Group 2: Opportunities in Smart Energy - The evolving electricity market presents opportunities for digital and informational support, as market participants face complex trading scenarios [4] - Key areas for improvement include AI-based power forecasting, load forecasting, and multi-energy collaborative trading decisions [4] - The company aims to leverage these needs to enhance its information technology offerings in electricity trading [4] Group 3: Artificial Intelligence Initiatives - The company has developed an AI platform, "Yuan Guang Tian Feng," integrating various large models and enabling automated service generation [5][6] - It has launched enterprise-level intelligent applications, enhancing user interaction and operational efficiency [6] - The integration of AI with IoT and biometric technologies has led to the development of smart hardware products [6] Group 4: Market Value Management Strategies - The company is committed to enhancing value creation through strategic planning and investment in key technologies like cloud computing and AI [7] - It emphasizes transparency in information disclosure to improve investor understanding and confidence [7] - The company will utilize various market value management tools to boost market confidence as needed [7]

Group 1: Company Performance Overview - In the first half of 2025, the company achieved total revenue of 187 million yuan, a decrease of 5.14% compared to the same period last year [3] - Net profit attributable to shareholders was 46.49 million yuan, down 45.97% year-on-year [3] - Earnings per share were 0.26 yuan, reflecting a decline of 45.83% compared to the previous year [3] Group 2: Key Product Performance - The main revenue sources were oral repair membranes and meningeal series products, with meningeal products generating sales of 80.27 million yuan [3] - Oral repair membranes achieved sales of 77.12 million yuan despite increased competition and demand fluctuations [3] - New product active biological bone showed steady growth, with hospital admissions meeting targets and sales gradually increasing [3][4] Group 3: Future Product Development - The new oral repair membrane product has received certification, and calcium silicate biological ceramic bone repair materials are in the registration phase, expected to enhance the company's product portfolio [4] - Other pipeline products, including uterine repair membranes and breast patches, are in the registration and data management stages, anticipated to contribute to revenue in the next 2-3 years [4] Group 4: Market Challenges and Strategies - The decline in revenue was primarily due to decreased income from the oral sector, driven by weak demand in the implant market and intensified competition [6] - The company plans to continue focusing on its strengths and developing new products to achieve stable revenue growth [6] - The impact of centralized procurement on meningeal product pricing has led to a decrease in prices but an increase in sales volume [7] Group 5: International Expansion Plans - The company is exploring the potential for some products to enter international markets and is currently planning related activities [7]

Group 1: Acquisition Strategy - The acquisition of Damo Semiconductor is a key strategic move for the company to explore new growth avenues and address challenges in its main business due to market competition and global trade tensions [3][4] - The acquisition aligns with the company's goal to enter the semiconductor front-end measurement equipment sector, which is expected to provide a sustainable growth path [3][4] Group 2: Financial Performance of Damo Semiconductor - Damo Semiconductor's revenue grew from CNY 191.0 million in 2022 to CNY 277.9 million in 2024, with a compound annual growth rate (CAGR) of 20.62% [4] - Net profit increased from CNY 47.7 million in 2022 to CNY 64.9 million in 2024, achieving a CAGR of 16.62% [4] Group 3: Investment and Stock Purchase - 36% of the transaction price will be used to purchase the company's stock from the secondary market, aimed at aligning the interests of the stock transfer party with the long-term goals of the company [5] - This arrangement is designed to incentivize the performance of Damo Semiconductor, thereby supporting the overall growth and stability of the company's market value [5] Group 4: Competitive Advantages - Damo Semiconductor offers significant price advantages with its repair equipment, which is priced lower than new equipment, reducing customer procurement costs [6] - The company boasts efficient delivery capabilities, providing shorter lead times compared to international brands [6] - Reliable operational and maintenance services ensure long-term stable operation of equipment, maximizing production line efficiency for clients [6][7] Group 5: Maintenance and Technical Services - Damo Semiconductor provides comprehensive maintenance services, including preventive maintenance, fault diagnosis, and performance optimization, ensuring equipment stability and enhancing client production efficiency [7] - The company has established competitive barriers in maintenance services through technical talent, spare parts supply chains, and customer resources [8] Group 6: Future Development Plans - Damo Semiconductor plans to expand its maintenance services in the mature process market while also targeting advanced processes to support domestic key clients facing challenges in obtaining original factory support [9] - The company aims to increase its market share in maintenance services for existing clients, leveraging its established relationships [9] Group 7: Main Business Focus - The company is enhancing its marketing efforts in non-U.S. markets, which now account for 85.37% of its sales, while optimizing its domestic marketing network [12] - New product development, including electric all-terrain vehicles and cleaning vehicles, is being accelerated to improve competitiveness [12]

Group 1: Company Overview and Business Scope - The company has over 20 years of expertise in intelligent logistics and manufacturing equipment, primarily serving the tobacco industry with integrated solutions [2] - Main business areas include intelligent logistics systems, production line systems, operation maintenance, and specialized products and services [2] - The company is expanding its technology applications from the tobacco industry to other sectors such as liquor and energy chemicals, developing a range of high-quality solutions and proprietary products [2] Group 2: International Market Development - The company is actively pursuing international market expansion while focusing on domestic growth, aligning with the "Belt and Road" initiative to support national strategies [3] Group 3: Robotics and Technology Advancements - The company is one of the early domestic developers of AGV (Automated Guided Vehicle) technology, holding complete proprietary rights and recognized as a "Famous Brand" in Yunnan Province [3] - New technologies such as communication, artificial intelligence, big data, and cloud technology are being integrated into smart equipment to enhance the capabilities of industrial robots [3] - Continuous optimization of the mobile robot control system software platform is planned for 2024, enabling intelligent collaborative scheduling in complex scenarios [3]

Group 1: Company Overview and Management - The company is one of the earliest in China to engage in industrial equipment anti-corrosion and wear-resistant overlay welding, leveraging strong technical expertise and product quality to build a reputable brand image [1] - The management adopts a project-based approach, with a project manager responsible for overseeing execution, ensuring quality control, and providing technical support post-project completion [2] Group 2: Market Opportunities and Collaborations - The company plans to establish a joint venture with Wilham, focusing on expanding into the oil and gas market, particularly in the Middle East, to set up overseas manufacturing bases [4] - There is a growing demand for bimetallic metallurgical composite pipes in the oil and gas industry due to increased corrosion risks in acidic gas fields, indicating a significant market opportunity [4][5] Group 3: Industry Competition and Strategy - The industrial anti-corrosion and wear-resistant overlay welding market is expanding, driven by the rapid growth of waste incineration power generation in China, attracting more competitors [6] - To address increasing competition, the company will enhance R&D investment and innovation, focusing on new materials, processes, and equipment to improve product diversity and operational efficiency [6]

Group 1: Financial Performance and Projections - The contribution of the agricultural CDMO business to revenue is expected to remain around 50% for both 2023 and 2024 [1] - The company anticipates gradual recovery in the agricultural sector, with improved demand from downstream customers [25] - The company has conducted reasonable impairment provisions for goodwill in 2023 and 2024, with risks of further impairment existing [12] Group 2: Market Trends and Competitive Landscape - The market for chlorantraniliprole intermediates is experiencing intense competition due to a surge in domestic production capacity, impacting raw material prices [2][3] - The company maintains a "big client strategy" to navigate the competitive landscape and enhance cost control for downstream clients [3] Group 3: Strategic Partnerships and Collaborations - The company has established a strategic partnership with Hengrui Medicine, focusing on a full lifecycle collaboration model for product development and commercialization [7][8] - The collaboration with Hengrui is expected to cover major therapeutic areas, including oncology and cardiovascular diseases, with a focus on supply chain needs [8][16] Group 4: Production Capacity and Development Plans - The company is in the process of upgrading its production bases, with a focus on core raw material production and innovative product development [9][14] - The Lanzhou base is expected to see performance improvements as the agricultural sector recovers and customer demand increases [13] Group 5: Risk Management and Inventory Control - The company employs dynamic inventory management based on historical sales data and market trends to ensure stable supply for major clients [11] - The company is closely monitoring international trade policies and their impact on export operations, maintaining flexibility in supply chain management [14]